Literature DB >> 3599020

Peptide quantitative structure-activity relationships, a multivariate approach.

S Hellberg, M Sjöström, B Skagerberg, S Wold.   

Abstract

The variation in amino acid sequence within sets of peptides is described by three principal properties, z1, z2, and z3, per varied amino acid position. These principal properties are derived from a principal components analysis of a matrix of 29 physicochemical variables for the 20 coded (in mRNA) amino acids. The scales z1, z2, and z3 are used to construct informative sets of analogues for exploring and developing quantitative structure-activity relationships (QSAR) of peptides. For the QSARs, the multivariate partial least squares (PLS) method is used. Multivariate QSARs are developed for four families of peptides, and it is shown how these QSARs can predict the activity of new peptide analogues.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3599020     DOI: 10.1021/jm00390a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  61 in total

1.  Classification of G-protein coupled receptors by alignment-independent extraction of principal chemical properties of primary amino acid sequences.

Authors:  Maris Lapinsh; Alexandrs Gutcaits; Peteris Prusis; Claes Post; Torbjörn Lundstedt; Jarl E S Wikberg
Journal:  Protein Sci       Date:  2002-04       Impact factor: 6.725

2.  Flexsim-R: a virtual affinity fingerprint descriptor to calculate similarities of functional groups.

Authors:  Alexander Weber; Andreas Teckentrup; Hans Briem
Journal:  J Comput Aided Mol Des       Date:  2002-12       Impact factor: 3.686

3.  PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.

Authors:  T Lotta; J Taskinen; R Bäckström; E Nissinen
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

Review 4.  Designing antimicrobial peptides: form follows function.

Authors:  Christopher D Fjell; Jan A Hiss; Robert E W Hancock; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

5.  Structure-based characterization of the binding of peptide to the human endophilin-1 Src homology 3 domain using position-dependent noncovalent potential analysis.

Authors:  Chunjiang Fu; Gang Wu; Fenglin Lv; Feifei Tian
Journal:  J Mol Model       Date:  2011-09-27       Impact factor: 1.810

6.  QSAR study on angiotensin-converting enzyme inhibitor oligopeptides based on a novel set of sequence information descriptors.

Authors:  Xiaoyu Wang; Juan Wang; Yong Lin; Yuan Ding; Yuanqiang Wang; Xiaoming Cheng; Zhihua Lin
Journal:  J Mol Model       Date:  2010-10-13       Impact factor: 1.810

7.  A comprehensive analysis of the thermodynamic events involved in ligand-receptor binding using CoRIA and its variants.

Authors:  Jitender Verma; Vijay M Khedkar; Arati S Prabhu; Santosh A Khedkar; Alpeshkumar K Malde; Evans C Coutinho
Journal:  J Comput Aided Mol Des       Date:  2008-01-25       Impact factor: 3.686

Review 8.  Protein quadratic indices of the "macromolecular pseudograph's alpha-carbon atom adjacency matrix". 1. Prediction of Arc repressor alanine-mutant's stability.

Authors:  Yovani Marrero Ponce; Ricardo Medina Marrero; Eduardo A Castro; Ronal Ramos de Armas; Humberto González Díaz; Vicente Romero Zaldivar; Francisco Torrens
Journal:  Molecules       Date:  2004-12-31       Impact factor: 4.411

9.  Vicinity analysis: a methodology for the identification of similar protein active sites.

Authors:  A McGready; A Stevens; M Lipkin; B D Hudson; D C Whitley; M G Ford
Journal:  J Mol Model       Date:  2008-12-16       Impact factor: 1.810

10.  A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Authors:  T Hertz; M G Logan; M Rolland; C A Magaret; C Rademeyer; A Fiore-Gartland; P T Edlefsen; A DeCamp; H Ahmed; N Ngandu; B B Larsen; N Frahm; J Marais; R Thebus; D Geraghty; J Hural; L Corey; J Kublin; G Gray; M J McElrath; J I Mullins; P B Gilbert; C Williamson
Journal:  Vaccine       Date:  2016-10-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.